Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$69.00 USD

69.00
3,405,133

-0.70 (-1.00%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks News

BD's Onclarity HPV PMA Submission to Boost Women's Health

Becton, Dickinson (BDX) offers a wide range of next-generation solutions in the field of cervical, ovarian and breast cancer.

San Gorgonio Hospital Picks Allscripts Sunrise Community Care

Allscripts' (MDRX) Sunrise Community Care is an Azure-hosted platform offering clinical, financial and ambulatory content.

Sanghamitra Saha headshot

Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

NextGen's Medfusion Buyout to Improve Patient Experience

NextGen (NXGN) showcases new capabilities and services for its flagship NextGen Enterprise platform.

Nilanjan Choudhury headshot

5 Relative Price Strength Stocks to Buy for Optimum Returns

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

Is (DXCM) Outperforming Other Medical Stocks This Year?

The Zacks Analyst Blog Highlights: Dexcom, Fortinet and Agnico Eagle

The Zacks Analyst Blog Highlights: Dexcom, Fortinet and Agnico Eagle

John Blank headshot

A Struggle to Find Revenue Growth: Global Week Ahead

About 90% of S&P 500 companies have reported results as of Friday, Nov. 8th. 72.5% have beaten EPS estimates. Only 57.9% beat revenue estimates. A low Q3 revenue beat number (57.8%) is worrisome!

What Makes DexCom (DXCM) a Strong Momentum Stock: Buy Now?

Does DexCom (DXCM) have what it takes to be a top stock pick for momentum investors? Let's find out.

DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DexCom (DXCM) Earnings and Revenues Beat Estimates in Q3

DexCom's (DXCM) Q3 earnings benefit from higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook. However, contraction in gross margin remains a woe.

DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?

DexCom's (DXCM) Q3 earnings is likely to reflect top-line growth and rising global awareness of the company's real-time CGM.

DexCom's (DXCM) New G6 Pro CGM System Gets FDA Approval

FDA approval for DexCom's (DXCM) G6 Pro boosts the company's broad product spectrum.

Neena Mishra headshot

Stocks & ETF to Invest in Healthcare Robotics and Innovation

HTEC is poised to benefit from rapid advances in health-care technology

Neena Mishra headshot

Stocks & ETF to Invest in Healthcare Robotics and Innovation

HTEC is poised to benefit from rapid advances in health-care technology.

Urmimala Biswas headshot

CGM Devices Gain Steam, Set New Trend in Diabetes Management

The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.

Urmimala Biswas headshot

IoMT Becomes the Buzzword in New Age MedTech Investing

Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

DexCom (DXCM) continues to benefit from growing glucose monitoring market, strategic buyouts and strong international presence. However, margin contraction remains a woe.

DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?

DexCom (DXCM) has various favorable factors to maintain the current high.

DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates

Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. However, contraction in gross margin remains a woe.

DexCom (DXCM) Hits 52-Week High, Can the Run Continue?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More

Solid growth in emerging markets is expected to be an added positive this earnings season.

What's in the Offing for DexCom's (DXCM) Earnings in Q2?

Top-line growth and rising global awareness of the company's real-time CGM are likely to aid DexCom's (DXCM) Q2 earnings.

DexCom (DXCM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Benjamin Rains headshot

3 Internet of Things Stocks to Buy for July

Today we've highlighted three, Zacks buy-ranked stocks with growing IoT businesses that investors might want to consider at the moment...